Clinical-trials tracker

How much human testing each peptide is actually getting: total registered studies, how many are recruiting, how many are still active, and how many have finished — with the highest phase reached. The metabolic peptides dominate; most research peptides have a handful of trials or none.

Data as of October 11, 2026 ·15,898 trials across 78 compounds

15,898trials tracked
78compounds in trials
1,417recruiting now
40notable open studies

Search a compound

78 compounds shown

Trial counts per compound. Click a column heading to sort.
Compound	Total	Recruiting	Active	Completed	Top phase
L-TyrosineAmino acid	2,101	57	32	10	Phase 4
L-PhenylalanineAmino acid	1,074	58	25	15	Phase 4
GABAAmino acid	1,061	49	6	39	Phase 4
L-SerineAmino acid	835	58	14	23	Phase 4
L-ArginineAmino acid	784	50	11	33	Phase 4
SemaglutidePeptide · Incretin / metabolic	779	57	20	23	Phase 4
L-CysteineAmino acid	721	48	12	35	Phase 4
NAC (N-acetylcysteine)Amino acid	674	45	16	31	Phase 4
L-DOPA (levodopa)Amino acid	618	45	13	39	Phase 4
LiraglutidePeptide · Incretin / metabolic	514	32	11	43	Phase 4
L-ValineAmino acid	443	42	7	33	Phase 4
ExenatidePeptide · Incretin / metabolic	378	13	6	56	Phase 4
AlanineAmino acid	365	52	21	23	Phase 4
CreatineAmino acid	362	53	4	40	Phase 4
L-LeucineAmino acid	319	55	7	29	Phase 3
L-Carnitine / ALCARAmino acid	312	26	11	46	Phase 4
TirzepatidePeptide · Incretin / metabolic	298	77	12	11	Phase 4
L-GlutamineAmino acid	290	35	4	37	Phase 4
GlutathioneAmino acid	271	33	13	42	Phase 4
NAD+Peptide · Longevity / mitochondrial	267	57	6	32	Phase 4
GlycineAmino acid	244	23	11	47	Phase 4
L-LysineAmino acid	216	24	11	41	Phase 4
L-MethionineAmino acid	212	25	11	41	Phase 4
HomocysteineAmino acid	188	20	2	52	Phase 4
L-TryptophanAmino acid	174	31	8	45	Phase 4
L-ProlineAmino acid	173	21	4	44	Phase 4
L-CitrullineAmino acid	162	21	2	56	Phase 4
L-Glutamic acidAmino acid	159	16	17	37	Phase 4
TaurineAmino acid	154	21	4	53	Phase 4
L-HistidineAmino acid	143	26	7	40	Phase 4
DulaglutidePeptide · Incretin / metabolic	142	19	4	63	Phase 4
L-OrnithineAmino acid	124	17	10	51	Phase 4
L-ThreonineAmino acid	114	20	9	44	Phase 4
Aspartic acidAmino acid	105	12	7	59	Phase 4
Beta-alanineAmino acid	87	13	7	54	Phase 4
Betaine (TMG)Amino acid	81	14	3	47	Phase 4
SAMeAmino acid	71	11	2	44	Phase 4
Thymosin alpha-1Peptide · Immune / antimicrobial	65	17	2	24	Phase 4
L-IsoleucineAmino acid	60	9	3	31	Phase 4
L-TheanineAmino acid	56	9	0	44	Phase 4
CarnosineAmino acid	53	2	1	36	Phase 4
OrforglipronPeptide · Incretin / metabolic	53	13	8	32	Phase 4
CagrilintidePeptide · Incretin / metabolic	44	11	7	24	Phase 3
CerebrolysinPeptide · Nootropic / mental-health	43	8	1	19	Phase 4
MazdutidePeptide · Incretin / metabolic	43	21	3	18	Phase 4
RetatrutidePeptide · Incretin / metabolic	33	2	10	21	Phase 3
CagriSemaPeptide · Incretin / metabolic	31	6	5	18	Phase 3
5-HTPAmino acid	29	6	1	18	Phase 4
LarazotidePeptide · Healing / recovery	29	1	2	22	Phase 3
SurvodutidePeptide · Incretin / metabolic	29	8	3	18	Phase 3
SermorelinPeptide · GH secretagogues	27	1	0	21	Phase 4
SetmelanotidePeptide · Melanocortin	27	3	2	19	Phase 4
TesamorelinPeptide · GH secretagogues	24	3	0	14	Phase 4
Melanotan I (afamelanotide)Peptide · Melanocortin	23	0	1	18	Phase 3
DefensinsPeptide · Immune / antimicrobial	22	1	0	7	Phase 4
SS-31 (elamipretide)Peptide · Longevity / mitochondrial	21	2	2	14	Phase 4
LL-37Peptide · Immune / antimicrobial	20	2	0	12	Phase 3
VIP (vasoactive intestinal peptide)Peptide · Healing / recovery	20	1	1	13	Phase 4
Thymosin beta-4Peptide · Healing / recovery	18	3	0	11	Phase 3
FollistatinPeptide · GH secretagogues	15	2	1	11	Phase 4
AsparagineAmino acid	14	0	2	10	Phase 3
TesofensinePeptide · Incretin / metabolic	13	0	0	11	Phase 2
Citrulline malateAmino acid	11	0	1	6	Phase 2
HydroxyprolineAmino acid	10	0	0	6	Phase 4
PT-141 (bremelanotide)Peptide · Melanocortin	10	0	1	9	Phase 4
MK-677 (ibutamoren)Peptide · GH secretagogues	8	1	0	5	Phase 3
Argireline (acetyl hexapeptide-8)Peptide · Cosmetic / skin	6	0	0	5	Phase 3
MOTS-cPeptide · Longevity / mitochondrial	5	3	1	0	Phase 2
ARA-290 (cibinetide)Peptide · Healing / recovery	4	0	0	2	Phase 2
BPC-157Peptide · Healing / recovery	4	2	0	1	Phase 2
HumaninPeptide · Longevity / mitochondrial	3	1	0	1	N/A
IpamorelinPeptide · GH secretagogues	3	0	1	2	Phase 2
SelankPeptide · Nootropic / mental-health	2	0	0	1	N/A
CJC-1295Peptide · GH secretagogues	1	0	0	0	Phase 2
GHK-CuPeptide · Cosmetic / skin	1	1	0	0	Phase 2
Melanotan IIPeptide · Melanocortin	1	1	0	0	Phase 2
SelenocysteineAmino acid	1	0	0	1	Phase 1
TB-500Peptide · Healing / recovery	1	1	0	0	Phase 2

What's actively recruiting right now

These studies are open and enrolling as of the date above — the leading edge of peptide research. Retatrutide and the other incretin drugs are running large Phase 3 programs; a few research peptides (BPC-157 among them) have small early-phase trials underway. Each links to its ClinicalTrials.gov record.

Open, actively-recruiting trials, most-advanced phase first.
Compound	Phase	Status	Study	Sponsor	Primary completion
GABA	Phase 4	Not yet recruiting	NCT07859839Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD	Post Graduate Institute of Medical Education and Research, Chandigarh	Jun 30, 2027
GABA	Phase 4	Enrolling (invitation)	NCT07750639Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity	AdventHealth	Nov 30, 2027
GABA	Phase 4	Recruiting	NCT07840183Epidural Analgesia Versus Opioid-sparing Analgesia for Open Ventral Hernia Repair With Transversus Abdominis Release	Northwestern University	Sep 2027
L-Carnitine / ALCAR	Phase 4	Not yet recruiting	NCT07862725Comparative Efficacy of Antioxidants Alone Versus Combined Therapy With SERMs or FSH in Normogonadotropic Idiopathic OAT Patients: A Randomized Controlled Trial	Hamad Medical Corporation	Oct 15, 2027
Tirzepatide	Phase 4	Recruiting	NCT07218445The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity	Mayo Clinic	Sep 18, 2027
GABA	Phase 4	Recruiting	NCT06379425Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries	Northwell Health	Jan 1, 2027
NAD+	Phase 4	Not yet recruiting	NCT07832084Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s	Jing Luo	Apr 30, 2027
Semaglutide	Phase 4	Not yet recruiting	NCT07859150Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)	General Committee of Teaching Hospitals and Institutes, Egypt	Apr 2029
Semaglutide	Phase 4	Recruiting	NCT06706284Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes	Marzieh Salehi	Sep 1, 2028
Semaglutide	Phase 4	Not yet recruiting	NCT07859163Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain	General Committee of Teaching Hospitals and Institutes, Egypt	Apr 2029
Semaglutide	Phase 4	Not yet recruiting	NCT07859176Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery	General Committee of Teaching Hospitals and Institutes, Egypt	Apr 2028
Semaglutide	Phase 4	Not yet recruiting	NCT07858331Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access	Kristin Clemens	Jan 1, 2029
Semaglutide	Phase 4	Not yet recruiting	NCT07832084Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s	Jing Luo	Apr 30, 2027
Semaglutide	Phase 4	Not yet recruiting	NCT07859189Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery	General Committee of Teaching Hospitals and Institutes, Egypt	Oct 2028
Semaglutide	Phase 4	Not yet recruiting	NCT07859137Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher	General Committee of Teaching Hospitals and Institutes, Egypt	Nov 2028
Tirzepatide	Phase 4	Not yet recruiting	NCT07832084Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s	Jing Luo	Apr 30, 2027
Semaglutide	Phase 4	Not yet recruiting	NCT06977438GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward	University of Minnesota	Jan 31, 2031
L-Serine	Phase 4	Recruiting	NCT06571149Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake	Insel Gruppe AG, University Hospital Bern	Jan 31, 2029
L-DOPA (levodopa)	Phase 4	Recruiting	NCT07839793A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients	Navamedic AB	Mar 31, 2027
L-Tyrosine	Phase 4	Not yet recruiting	NCT07839988De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid Leukemia	Nanfang Hospital, Southern Medical University	Jul 31, 2030
L-Carnitine / ALCAR	Phase 4	Recruiting	NCT07642076Evaluation of the Clinical Impact of Adjunctive L-carnitine Therapy in Critically Ill Hepatic Patients Admitted to Intensive Care Unit	Beni-Suef University	Dec 2026
Mazdutide	Phase 4	Recruiting	NCT07718126Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)	West China Hospital	Feb 28, 2029
L-Serine	Phase 4	Not yet recruiting	NCT07816978Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism	Sahlgrenska University Hospital	Jan 31, 2030
Mazdutide	Phase 4	Not yet recruiting	NCT07824895Mazdutide for Weight Management and Gout in Adults With Obesity	Hongwei Jiang	Dec 31, 2027
SS-31 (elamipretide)	Phase 4	Recruiting	NCT07531251Clinical Trial in Patients With Barth Syndrome- 4TAZPower	Stealth BioTherapeutics Inc.	Sep 30, 2029
Tirzepatide	Phase 4	Recruiting	NCT07777575Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide	Technical University of Munich	May 31, 2027
L-Cysteine	Phase 4	Recruiting	NCT07273071Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine	Theis S. Itenov	Feb 2028
NAC (N-acetylcysteine)	Phase 4	Recruiting	NCT07273071Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine	Theis S. Itenov	Feb 2028
L-Serine	Phase 4	Recruiting	NCT07145866Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)	Massachusetts General Hospital	Sep 2028
Tirzepatide	Phase 4	Recruiting	NCT07191873Tirzepatide in Idiopathic Intracranial Hypertension Trial	Duke University	Aug 2027
GABA	Phase 4	Recruiting	NCT07813026Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users	Viatris Inc.	Jan 31, 2027
L-Serine	Phase 4	Recruiting	NCT06010628Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)	General Hospital of Shenyang Military Region	Dec 15, 2029
Semaglutide	Phase 4	Recruiting	NCT06132477Impact GLP-1 Agonists Following Bariatric	University of Missouri-Columbia	Jul 2028
L-DOPA (levodopa)	Phase 4	Not yet recruiting	NCT07806019Metformin in Parkinson's Disease: Safety and Efficacy	Jinnah Medical & Dental College	Feb 1, 2027
Tirzepatide	Phase 4	Recruiting	NCT07247084A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)	Eli Lilly and Company	Jul 2029
Tirzepatide	Phase 4	Recruiting	NCT06857942A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)	Eli Lilly and Company	May 2028
L-DOPA (levodopa)	Phase 4	Recruiting	NCT06234995Cortical Electrophysiology of Response Inhibition in Parkinson's Disease	Emory University	Sep 2027
L-Phenylalanine	Phase 4	Recruiting	NCT06234995Cortical Electrophysiology of Response Inhibition in Parkinson's Disease	Emory University	Sep 2027
Taurine	Phase 4	Recruiting	NCT06269627Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Dec 31, 2026
L-Histidine	Phase 4	Recruiting	NCT06799494HPV Vaccine Reduced Dose	Emory University	Sep 2028

How this tracker is built

Counts come from the ClinicalTrials.gov API (v2), queried by intervention name for each compound. Total is every registered study; recruitingcounts those actively enrolling; active means underway but no longer recruiting; completed means the study has finished. A compound with zero trials simply isn't listed here — an honest gap, not a hidden row. The table refreshes whenever the site rebuilds, so the "as of" date is the real freshness.